TY - JOUR
T1 - Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging
AU - Vivian, Diana
AU - Cheng, Kunrong
AU - Khurana, Sandeep
AU - Xu, Su
AU - Dawson, Paul A.
AU - Raufman, Jean Pierre
AU - Polli, James E.
N1 - Funding Information:
This work was supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (grants DK-093406, DK-067872, DK-047987, and DK-081479), National Cancer Institute (grant CA-120407), and the Food and Drug Administration (collaborative agreement U01FD004320).
Publisher Copyright:
© 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
PY - 2014/11
Y1 - 2014/11
N2 - Previously, we developed a trifluorinated bile acid, CA-lys-TFA, with the objective of noninvasively assessing bile acid transport in vivo using 19F magnetic resonance imaging (MRI). CA-lys-TFA was successfully imaged in the mouse gallbladder, but was susceptible to deconjugation in vitro by choloylglycine hydrolase (CGH), a bacterial bile acid deconjugating enzyme found in the terminal ileum and colon. The objective of the present study was to develop a novel trifluorinated bile acid resistant to deconjugation by CGH. CA-sar-TFMA was designed, synthesized, and tested for in vitro transport properties, stability, imaging properties, and its ability to differentially accumulate in the gallbladders of normal mice, compared with mice with known impaired bile acid transport (deficient in the apical sodium-dependent bile acid transporter, ASBT). CA-sar-TFMA was a potent inhibitor and substrate of ASBT and the Na+/taurocholate cotransporting polypeptide. Stability was favorable in all conditions tested, including the presence of CGH. CA-sar-TFMA was successfully imaged and accumulated at 16.1-fold higher concentrations in gallbladders from wild-type mice compared with those from Asbt-deficient mice. Our results support the potential of using MRI with CA-sar-TFMA as a noninvasive method to assess bile acid transport in vivo.
AB - Previously, we developed a trifluorinated bile acid, CA-lys-TFA, with the objective of noninvasively assessing bile acid transport in vivo using 19F magnetic resonance imaging (MRI). CA-lys-TFA was successfully imaged in the mouse gallbladder, but was susceptible to deconjugation in vitro by choloylglycine hydrolase (CGH), a bacterial bile acid deconjugating enzyme found in the terminal ileum and colon. The objective of the present study was to develop a novel trifluorinated bile acid resistant to deconjugation by CGH. CA-sar-TFMA was designed, synthesized, and tested for in vitro transport properties, stability, imaging properties, and its ability to differentially accumulate in the gallbladders of normal mice, compared with mice with known impaired bile acid transport (deficient in the apical sodium-dependent bile acid transporter, ASBT). CA-sar-TFMA was a potent inhibitor and substrate of ASBT and the Na+/taurocholate cotransporting polypeptide. Stability was favorable in all conditions tested, including the presence of CGH. CA-sar-TFMA was successfully imaged and accumulated at 16.1-fold higher concentrations in gallbladders from wild-type mice compared with those from Asbt-deficient mice. Our results support the potential of using MRI with CA-sar-TFMA as a noninvasive method to assess bile acid transport in vivo.
KW - Bile acid malabsorption
KW - Bile acid transporters
KW - Biliary excretion
KW - Enterohepatic circulation
KW - Fluorine MRI
KW - Imaging methods
KW - Intestinal absorption
KW - Site-specific delivery
KW - Targeted drug delivery
KW - Transporters
UR - http://www.scopus.com/inward/record.url?scp=84914818339&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84914818339&partnerID=8YFLogxK
U2 - 10.1002/jps.24131
DO - 10.1002/jps.24131
M3 - Article
C2 - 25196788
AN - SCOPUS:84914818339
SN - 0022-3549
VL - 103
SP - 3782
EP - 3792
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 11
ER -